Cargando…

Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

AIMS: To describe the natural history of SARS‐CoV‐2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gimeno, Juan R., Olivotto, Iacopo, Rodríguez, Ana Isabel, Ho, Carolyn Y., Fernández, Adrián, Quiroga, Alejandro, Espinosa, Mari Angeles, Gómez‐González, Cristina, Robledo, María, Tojal‐Sierra, Lucas, Day, Sharlene M., Owens, Anjali, Barriales‐Villa, Roberto, Larrañaga, Jose María, Rodríguez‐Palomares, Jose, González‐del‐Hoyo, Maribel, Piqueras‐Flores, Jesús, Reza, Nosheen, Chumakova, Olga, Ashley, Euan A., Parikh, Victoria, Wheeler, Matthew, Jacoby, Daniel, Pereira, Alexandre C., Saberi, Sara, Helms, Adam S., Villacorta, Eduardo, Gallego‐Delgado, María, de Castro, Daniel, Domínguez, Fernando, Ripoll‐Vera, Tomás, Zorio‐Grima, Esther, Sánchez‐Martínez, José Carlos, García‐Álvarez, Ana, Arbelo, Elena, Mogollón, María Victoria, Fuentes‐Cañamero, María Eugenia, Grande, Elias, Peña, Carlos, Monserrat, Lorenzo, Lakdawala, Neal K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288745/
https://www.ncbi.nlm.nih.gov/pubmed/36255281
http://dx.doi.org/10.1002/ehf2.13964
_version_ 1784748515398778880
author Gimeno, Juan R.
Olivotto, Iacopo
Rodríguez, Ana Isabel
Ho, Carolyn Y.
Fernández, Adrián
Quiroga, Alejandro
Espinosa, Mari Angeles
Gómez‐González, Cristina
Robledo, María
Tojal‐Sierra, Lucas
Day, Sharlene M.
Owens, Anjali
Barriales‐Villa, Roberto
Larrañaga, Jose María
Rodríguez‐Palomares, Jose
González‐del‐Hoyo, Maribel
Piqueras‐Flores, Jesús
Reza, Nosheen
Chumakova, Olga
Ashley, Euan A.
Parikh, Victoria
Wheeler, Matthew
Jacoby, Daniel
Pereira, Alexandre C.
Saberi, Sara
Helms, Adam S.
Villacorta, Eduardo
Gallego‐Delgado, María
de Castro, Daniel
Domínguez, Fernando
Ripoll‐Vera, Tomás
Zorio‐Grima, Esther
Sánchez‐Martínez, José Carlos
García‐Álvarez, Ana
Arbelo, Elena
Mogollón, María Victoria
Fuentes‐Cañamero, María Eugenia
Grande, Elias
Peña, Carlos
Monserrat, Lorenzo
Lakdawala, Neal K.
author_facet Gimeno, Juan R.
Olivotto, Iacopo
Rodríguez, Ana Isabel
Ho, Carolyn Y.
Fernández, Adrián
Quiroga, Alejandro
Espinosa, Mari Angeles
Gómez‐González, Cristina
Robledo, María
Tojal‐Sierra, Lucas
Day, Sharlene M.
Owens, Anjali
Barriales‐Villa, Roberto
Larrañaga, Jose María
Rodríguez‐Palomares, Jose
González‐del‐Hoyo, Maribel
Piqueras‐Flores, Jesús
Reza, Nosheen
Chumakova, Olga
Ashley, Euan A.
Parikh, Victoria
Wheeler, Matthew
Jacoby, Daniel
Pereira, Alexandre C.
Saberi, Sara
Helms, Adam S.
Villacorta, Eduardo
Gallego‐Delgado, María
de Castro, Daniel
Domínguez, Fernando
Ripoll‐Vera, Tomás
Zorio‐Grima, Esther
Sánchez‐Martínez, José Carlos
García‐Álvarez, Ana
Arbelo, Elena
Mogollón, María Victoria
Fuentes‐Cañamero, María Eugenia
Grande, Elias
Peña, Carlos
Monserrat, Lorenzo
Lakdawala, Neal K.
author_sort Gimeno, Juan R.
collection PubMed
description AIMS: To describe the natural history of SARS‐CoV‐2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS‐Cov‐2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS‐CoV‐2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty‐nine (22.9%) HCM patients were hospitalized for non‐ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS‐CoV‐2‐related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12–4.51], P = 0.0229}, baseline New York Heart Association class [OR per one‐unit increase 4.01 (95%CI: 1.75–9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16–26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20–49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community‐based SARS‐CoV‐2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98–2.91, P = 0.0600). CONCLUSIONS: Over one‐fourth of HCM patients infected with SARS‐Cov‐2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.
format Online
Article
Text
id pubmed-9288745
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92887452022-07-19 Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry Gimeno, Juan R. Olivotto, Iacopo Rodríguez, Ana Isabel Ho, Carolyn Y. Fernández, Adrián Quiroga, Alejandro Espinosa, Mari Angeles Gómez‐González, Cristina Robledo, María Tojal‐Sierra, Lucas Day, Sharlene M. Owens, Anjali Barriales‐Villa, Roberto Larrañaga, Jose María Rodríguez‐Palomares, Jose González‐del‐Hoyo, Maribel Piqueras‐Flores, Jesús Reza, Nosheen Chumakova, Olga Ashley, Euan A. Parikh, Victoria Wheeler, Matthew Jacoby, Daniel Pereira, Alexandre C. Saberi, Sara Helms, Adam S. Villacorta, Eduardo Gallego‐Delgado, María de Castro, Daniel Domínguez, Fernando Ripoll‐Vera, Tomás Zorio‐Grima, Esther Sánchez‐Martínez, José Carlos García‐Álvarez, Ana Arbelo, Elena Mogollón, María Victoria Fuentes‐Cañamero, María Eugenia Grande, Elias Peña, Carlos Monserrat, Lorenzo Lakdawala, Neal K. ESC Heart Fail Original Articles AIMS: To describe the natural history of SARS‐CoV‐2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS‐Cov‐2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS‐CoV‐2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty‐nine (22.9%) HCM patients were hospitalized for non‐ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS‐CoV‐2‐related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12–4.51], P = 0.0229}, baseline New York Heart Association class [OR per one‐unit increase 4.01 (95%CI: 1.75–9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16–26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20–49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community‐based SARS‐CoV‐2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98–2.91, P = 0.0600). CONCLUSIONS: Over one‐fourth of HCM patients infected with SARS‐Cov‐2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality. John Wiley and Sons Inc. 2022-06-03 /pmc/articles/PMC9288745/ /pubmed/36255281 http://dx.doi.org/10.1002/ehf2.13964 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Gimeno, Juan R.
Olivotto, Iacopo
Rodríguez, Ana Isabel
Ho, Carolyn Y.
Fernández, Adrián
Quiroga, Alejandro
Espinosa, Mari Angeles
Gómez‐González, Cristina
Robledo, María
Tojal‐Sierra, Lucas
Day, Sharlene M.
Owens, Anjali
Barriales‐Villa, Roberto
Larrañaga, Jose María
Rodríguez‐Palomares, Jose
González‐del‐Hoyo, Maribel
Piqueras‐Flores, Jesús
Reza, Nosheen
Chumakova, Olga
Ashley, Euan A.
Parikh, Victoria
Wheeler, Matthew
Jacoby, Daniel
Pereira, Alexandre C.
Saberi, Sara
Helms, Adam S.
Villacorta, Eduardo
Gallego‐Delgado, María
de Castro, Daniel
Domínguez, Fernando
Ripoll‐Vera, Tomás
Zorio‐Grima, Esther
Sánchez‐Martínez, José Carlos
García‐Álvarez, Ana
Arbelo, Elena
Mogollón, María Victoria
Fuentes‐Cañamero, María Eugenia
Grande, Elias
Peña, Carlos
Monserrat, Lorenzo
Lakdawala, Neal K.
Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
title Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
title_full Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
title_fullStr Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
title_full_unstemmed Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
title_short Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
title_sort impact of sars‐cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288745/
https://www.ncbi.nlm.nih.gov/pubmed/36255281
http://dx.doi.org/10.1002/ehf2.13964
work_keys_str_mv AT gimenojuanr impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT olivottoiacopo impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT rodriguezanaisabel impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT hocarolyny impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT fernandezadrian impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT quirogaalejandro impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT espinosamariangeles impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT gomezgonzalezcristina impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT robledomaria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT tojalsierralucas impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT daysharlenem impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT owensanjali impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT barrialesvillaroberto impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT larranagajosemaria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT rodriguezpalomaresjose impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT gonzalezdelhoyomaribel impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT piquerasfloresjesus impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT rezanosheen impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT chumakovaolga impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT ashleyeuana impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT parikhvictoria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT wheelermatthew impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT jacobydaniel impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT pereiraalexandrec impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT saberisara impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT helmsadams impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT villacortaeduardo impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT gallegodelgadomaria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT decastrodaniel impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT dominguezfernando impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT ripollveratomas impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT zoriogrimaesther impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT sanchezmartinezjosecarlos impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT garciaalvarezana impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT arbeloelena impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT mogollonmariavictoria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT fuentescanameromariaeugenia impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT grandeelias impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT penacarlos impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT monserratlorenzo impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT lakdawalanealk impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry
AT impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry